Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Advisory

Taro to Announce Third Quarter Results on February 3, 2020


Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2019, after the close of market on Monday, February 3, 2020.

The release will be accessible on Taro's website at www.taro.com.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.


These press releases may also interest you

at 10:25
Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society...

at 10:23
D2L Releases 2024 Sustainability Report
D2L Inc. ("D2L" or the "Company"), a global learning technology company, has released its second Sustainability Report. The report highlights progress D2L has made over the past year, including implementing an ethical approach to artificial...

at 10:20
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy...

at 10:20
BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024
The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy armcombination data from the...

at 10:15
T-Mobile Unveils BIG Moves to Help Small Businesses Grow
It's nearly Small Business Week and T-Mobile is going big for small business customers with deals starting April 25! T-Mobile is launching Business Unlimited Edge and new small business customers that add at least 10 or more lines can get up to a...

at 10:15
Sheppard Mullin Welcomes IP Partner Alex Chung in Washington D.C.
Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho "Alex" Chung, Ph.D. has joined the firm's Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at...

More news about Science and technology...


News published on and distributed by: